TR200103457T2 - 4-Fenil-Pirimidin Türevleri. - Google Patents

4-Fenil-Pirimidin Türevleri.

Info

Publication number
TR200103457T2
TR200103457T2 TR2001/03457T TR200103457T TR200103457T2 TR 200103457 T2 TR200103457 T2 TR 200103457T2 TR 2001/03457 T TR2001/03457 T TR 2001/03457T TR 200103457 T TR200103457 T TR 200103457T TR 200103457 T2 TR200103457 T2 TR 200103457T2
Authority
TR
Turkey
Prior art keywords
phenyl
pyrimidine derivatives
receptor
compounds
formula
Prior art date
Application number
TR2001/03457T
Other languages
English (en)
Inventor
Boes Michael
Galley Guido
Godel Thierry
Hoffmann Torsten
Hunkeler Walter
Schnider Patrick
Stadler Heinz
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of TR200103457T2 publication Critical patent/TR200103457T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Bulus, formül (I)'e ait bilesiklerle ve bunlarin farmasötik açidan kabul gören asit ilaveli tuzlariyla ilgilidir. Bilesiklerin, NK-1 alicisina iyi bir yakinlik gösterdikleri ve bu nedenle de bu aliciyla ilgili hastaliklarin tedavisinde kullanilabildikleri gösterilmistir.(Formül I)
TR2001/03457T 1999-05-31 2000-05-24 4-Fenil-Pirimidin Türevleri. TR200103457T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99110483 1999-05-31

Publications (1)

Publication Number Publication Date
TR200103457T2 true TR200103457T2 (tr) 2002-04-22

Family

ID=8238271

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03457T TR200103457T2 (tr) 1999-05-31 2000-05-24 4-Fenil-Pirimidin Türevleri.

Country Status (36)

Country Link
US (1) US6274588B1 (tr)
EP (1) EP1187815B1 (tr)
JP (1) JP3590592B2 (tr)
KR (1) KR100440106B1 (tr)
CN (1) CN1166643C (tr)
AR (1) AR024146A1 (tr)
AT (1) ATE317389T1 (tr)
AU (1) AU770786B2 (tr)
BR (1) BR0011127A (tr)
CA (1) CA2375671C (tr)
CO (1) CO5170520A1 (tr)
CZ (1) CZ20014271A3 (tr)
DE (1) DE60025918T2 (tr)
DK (1) DK1187815T3 (tr)
ES (1) ES2257294T3 (tr)
GC (1) GC0000191A (tr)
HK (1) HK1046528B (tr)
HR (1) HRP20010871A2 (tr)
HU (1) HUP0201315A3 (tr)
IL (2) IL146460A0 (tr)
JO (1) JO2261B1 (tr)
MA (1) MA26793A1 (tr)
MX (1) MXPA01012089A (tr)
MY (1) MY122731A (tr)
NO (1) NO321354B1 (tr)
NZ (1) NZ515407A (tr)
PE (1) PE20010153A1 (tr)
PL (1) PL353441A1 (tr)
PT (1) PT1187815E (tr)
RU (1) RU2243221C2 (tr)
SI (1) SI1187815T1 (tr)
TR (1) TR200103457T2 (tr)
TW (1) TW550258B (tr)
WO (1) WO2000073279A1 (tr)
YU (1) YU84901A (tr)
ZA (1) ZA200109163B (tr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
EP1318147A1 (en) * 2000-09-14 2003-06-11 Ajinomoto Co., Inc. Novel pyrimidine derivative and novel pyridine derivative
MXPA03007395A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Derivados de pirimidin-5-carboxamida 2,4-disustituida como moduladores del canal de potasio kcnq.
JPWO2005040135A1 (ja) * 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
US7767680B2 (en) 2004-11-03 2010-08-03 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
ATE441633T1 (de) * 2005-02-22 2009-09-15 Hoffmann La Roche Nk1-antagonisten
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ．ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
US20060281712A1 (en) * 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
NZ588989A (en) 2008-04-21 2012-03-30 Taigen Biotechnology Co Ltd Heterocyclic compounds comprising pyrimidine, piperazine and amine.
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
EA038960B1 (ru) * 2015-01-30 2021-11-15 Басф Се Гербицидные фенилпиримидины
WO2018132326A1 (en) * 2017-01-10 2018-07-19 National Health Research Institutes Heterocyclic compounds and use thereof
KR102006547B1 (ko) * 2017-11-16 2019-08-01 서울대학교산학협력단 벤즈아미드 유도체 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 염증질환의 치료 또는 예방용 약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698340A (en) 1984-07-19 1987-10-06 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine derivatives, processes for preparation thereof and composition containing the same
DE3614060A1 (de) * 1986-04-23 1987-10-29 Schering Ag Pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als fungizide
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
CZ288176B6 (en) 1993-12-29 2001-05-16 Merck Sharp & Dohme Substituted morpholine derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical preparations in which they are comprised
CA2230894A1 (en) 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5972938A (en) 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders

Also Published As

Publication number Publication date
EP1187815B1 (en) 2006-02-08
EP1187815A1 (en) 2002-03-20
SI1187815T1 (sl) 2006-06-30
IL146460A0 (en) 2002-07-25
NO20015700L (no) 2001-11-22
CO5170520A1 (es) 2002-06-27
DE60025918T2 (de) 2006-09-28
CN1353697A (zh) 2002-06-12
IL146460A (en) 2006-10-31
CN1166643C (zh) 2004-09-15
NO20015700D0 (no) 2001-11-22
MY122731A (en) 2006-04-29
ES2257294T3 (es) 2006-08-01
KR100440106B1 (ko) 2004-07-14
HUP0201315A2 (hu) 2002-12-28
RU2243221C2 (ru) 2004-12-27
WO2000073279A1 (en) 2000-12-07
DE60025918D1 (de) 2006-04-20
KR20020000826A (ko) 2002-01-05
GC0000191A (en) 2006-03-29
PT1187815E (pt) 2006-06-30
MA26793A1 (fr) 2004-12-20
PE20010153A1 (es) 2001-02-08
ZA200109163B (en) 2003-02-06
HK1046528A1 (en) 2003-01-17
YU84901A (sh) 2004-09-03
CA2375671C (en) 2009-08-25
PL353441A1 (en) 2003-11-17
AR024146A1 (es) 2002-09-04
CA2375671A1 (en) 2000-12-07
HUP0201315A3 (en) 2003-02-28
HRP20010871A2 (en) 2003-04-30
AU4567700A (en) 2000-12-18
DK1187815T3 (da) 2006-06-19
JP3590592B2 (ja) 2004-11-17
MXPA01012089A (es) 2002-06-04
JO2261B1 (en) 2004-10-07
NO321354B1 (no) 2006-05-02
AU770786B2 (en) 2004-03-04
US6274588B1 (en) 2001-08-14
CZ20014271A3 (cs) 2002-05-15
HK1046528B (zh) 2005-02-25
NZ515407A (en) 2004-03-26
TW550258B (en) 2003-09-01
ATE317389T1 (de) 2006-02-15
BR0011127A (pt) 2002-02-19
JP2003500478A (ja) 2003-01-07

Similar Documents

Publication Publication Date Title
TR200103460T2 (tr) 5-Fenil-pirimidin türevleri
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
TR200000520A2 (tr) 4-Fenil-piridin türevleri.
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
JO2371B1 (en) 4-phenyl-pyridine derivatives
TR200102490T2 (tr) Fenil ve piridinil türevleri
DE50011582D1 (de) Neuartige dicarbonsäurederivate mit pharmazeutischen eigenschaften
JO2503B1 (en) Benzathiazole derivatives
TR199800436A2 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
TR200103457T2 (tr) 4-Fenil-Pirimidin Türevleri.
DE60045508D1 (de) Dalda-analoge und ihre verwendung
EA200200742A1 (ru) 1,2-диарилбензимидазолы для лечения заболеваний, связанных с активацией микроглии
TR200101649T2 (tr) Piperazin türevleri.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
PT775118E (pt) Derivados de benzimidazole com actividade dopaminergica
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
TR199901380A2 (tr) Di-ya da triazo-spiro[4,5] dekan türevleri
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
BR9814188A (pt) "agonistas de 5-ht1f"
HUP9904030A2 (hu) Tiagabin felhasználása pszichotikus rendellenességek kezelésére alkalmas gyógyszer előállítására
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
SE9802538D0 (sv) New pharmaceutically active compounds